Abstract
The use of quinolones in the treatment of non-serious community-acquired methicillin-resistant Staphylococcus aureus is discussed. The new C8-modified quinolones may be suitable for such treatment but controlled trials should be carried out to ensure that the pharmacokinetics are such that there is little risk of resistance developing.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 32-34 |
| Number of pages | 3 |
| Journal | International journal of antimicrobial agents |
| Volume | 24 |
| Issue number | 1 |
| DOIs |
|
| State | Published - Jul 2004 |
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Infectious Diseases
- Pharmacology (medical)
Keywords
- Community-acquired infections
- Fluoroquinolones
- Methicillin-resistance
- Staphylococcus aureus